Methadone
Methadose (methadone) is a small molecule pharmaceutical. Methadone was first approved as Dolophine hydrochloride on 1982-01-01. It is used to treat intractable pain and opioid-related disorders in the USA. The pharmaceutical is active against mu-type opioid receptor. In addition, it is known to target kappa-type opioid receptor and delta-type opioid receptor.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Methadose (generic drugs available since 1982-01-01, discontinued: Dolophine, Westadone)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| methadone hydrochloride methadose dispersible | ANDA | 2023-01-30 |
| methadone hydrocloride | ANDA | 2023-06-01 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| intractable pain | — | D010148 | — |
| opioid-related disorders | EFO_0005611 | D009293 | F11 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N02: Analgesics
— N02A: Opioid analgesics
— N02AC: Diphenylpropylamine derivative analgesics
— N02AC52: Methadone, combinations excl. psycholeptics
— N07: Other nervous system drugs in atc
— N07B: Drugs used in addictive disorders
— N07BC: Drugs used in opioid dependence
— N07BC02: Methadone
HCPCS
Code | Description |
|---|---|
| G2067 | Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a medicare-enrolled opioid treatment program) |
| G2078 | Take-home supply of methadone; up to 7 additional day supply (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure |
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) |
| J1230 | Injection, methadone hcl, up to 10 mg |
| S0109 | Methadone, oral, 5 mg |
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | METHADONE |
| INN | methadone |
| Description | Methadone is a racemate comprising equimolar amounts of dextromethadone and levomethadone. It is a opioid analgesic which is used as a painkiller and as a substitute for heroin in the treatment of heroin addiction. It has a role as an opioid analgesic, a mu-opioid receptor agonist, a xenobiotic, an environmental contaminant, a NMDA receptor antagonist and a serotonin uptake inhibitor. It contains a levomethadone and a dextromethadone. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 76-99-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL651 |
| ChEBI ID | 6807 |
| PubChem CID | 4095 |
| DrugBank | DB00333 |
| UNII ID | UC6VBE7V1Z (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 33,298 documents
View more details
Safety
Black-box Warning
Black-box warning for: Methadone hydrochloride methadose dispersible, Methadone hydrocloride
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more